oxaliplatin + cytarabine + capecitabine

Oxaliplatin + cytarabine + capecitabine (O-XAC) is an experimental combination chemotherapy regimen primarily investigated for the treatment of relapsed or refractory lymphomas. The regimen combines three distinct antineoplastic agents to achieve synergistic antitumor activity. **Oxaliplatin**, a third-generation platinum derivative, functions by forming bulky DNA adducts (intrastrand and interstrand cross-links) that inhibit DNA replication and transcription, leading to apoptosis. **Cytarabine** (Ara-C) is a pyrimidine nucleoside analog that, upon phosphorylation, competes with deoxycytidine triphosphate for incorporation into DNA and inhibits DNA polymerase, thereby halting DNA synthesis. **Capecitabine** is an orally administered fluoropyrimidine carbamate prodrug that is enzymatically converted to 5-fluorouracil (5-FU) within the body, particularly in tumor tissues; its active metabolite inhibits thymidylate synthase, depleting the thymidine pools necessary for DNA repair and synthesis. This triplet combination has been studied as a salvage therapy for patients with aggressive non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma who have failed prior treatments, offering an alternative to cisplatin-based regimens like DHAP with a potentially different toxicity profile.

Other names

Oxaliplatin-Cytarabine-Capecitabine regimenOXA-ARA-C-CAPE